Stock Updates

A look at a High Market Cap Stock: Celgene Corporation, CELG

Celgene Corporation, CELG is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, Celgene Corporation, CELGĀ  has a market cap of 80635.52. Since its IPO date on the 3/26/1990, Celgene Corporation, CELG performance year to date is -13.10%. Today Celgene Corporation, CELG has gained 0.04%, with a current price of 104.07.

Ownership of the company is 0.20% for insider ownership while institutional ownership is 79.30%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 7.20%, with return on investment at 8.90%.

In terms of debt levels and profit levels, Celgene Corporation, CELG is seeing a long-term debt/equity of 2.58. While Total debt/equity is 0. With a profit margin of 18.90%, this is combined with a gross margin of 95.70%, and operating margin of 27.10%. Celgene Corporation ability to meet debt levels, with a current ratio of 4.6, while the quick ratio is 4.4.

For the last year Celgene Corporation, CELG has seen a EPS growth of -18.80%. A performance for the year of -11.78%. The 52-week high is -18.94%, and the 52-week low is 11.84%. The average volume for Celgene Corporation, CELG is 1864900.

With a target price of 137.35, can Celgene Corporation, CELG reach this target? Looking at the value indicators of Celgene Corporation, CELG. Celgene Corporation has a P/E of 43.69 and a forward P/E of 14.88. Perhaps the more useful indicator than P/E, is PEG which has a value of 2. Celgene Corporation also has a P/S and a P/B of 7.93 and 14.56 respectively. For P/cash, Celgene Corporation has a value of 12.59, while it is 27.25 for P/free cash flow.

At the current price of 104.07, Celgene Corporation has a dividend yield of *TBA. We see a return on equity of 35.10%.

Looking more long-term Celgene Corporation, is projected to get an EPS growth for the next five years of 21.87%. In the short-term an EPS growth of 22.47% in the next year is forecasted. This is after a EPS growth of -18.80% for this year and for the last five years a 15.70% growth has been seen.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Peter Clarke

Leave a Comment